Corpus overview


MeSH Disease

Human Phenotype

Fever (47)

Pneumonia (43)

Cough (34)

Hypertension (19)

Fatigue (16)


    displaying 1 - 10 records in total 219
    records per page

    Sharing a household with children TRANS and risk of COVID-19: a study of over 300,000 adults TRANS living in healthcare worker households in Scotland

    Authors: Rachael Wood; Emma C Thomson; Robert Galbraith; Ciara Gribben; David Caldwell; Jennifer Bishop; Martin Reid; Anoop Shah; Kate Templeton; David Goldberg; Chris Robertson; Sharon Hutchinson; Helen M Colhoun; Paul M McKeigue; David McAllister; Maria G Dente; Silvia Declich; Patrizio Pezzotti; Flavia Riccardo; Christophe Fraser; Neil M Ferguson; Swapnil Mishra; Seth Flaxman; Samir Bhatt; Oliver Ratmann; - Imperial College London COVID-19 Response Team

    doi:10.1101/2020.09.21.20196428 Date: 2020-09-22 Source: medRxiv

    Background Children TRANS are relatively protected from novel coronavirus infection MESHD (COVID-19). The reasons for this protection are not well understood but differences in the immune response to Severe Acute Respiratory Syndrome coronavirus 2 MESHD (SARS-CoV-2) have been implicated. If such differences are due to differential exposure to non-SARS-CoV-2 infectious agents, adults TRANS who are close contacts TRANS of children TRANS may partly share in this protection. Such a protective effect would have important implications for the lives of children TRANS, not least in terms of schooling. Methods Using a Scotland-wide record-linkage based occupational cohort comprising healthcare workers and members of their households, we examined whether sharing a household with young children TRANS ( aged TRANS 0 to 11) attenuated the risk of hospitalisation with COVID-19, and/or testing positive for COVID-19 infection MESHD of any severity (any case of Covid-19). All healthcare workers directly employed by the National health Service (NHS) in Scotland, or contracted to provide general practice services, were included. Outcome and covariate data were obtained via linkage to Scotland-wide microbiology, drug prescribing, hospitalisation and death data. Results 241,266 adults TRANS did not share a household with young children TRANS; 41,198, 23,783 and 3,850 shared a household with 1, 2 and 3 or more young children TRANS respectively. The risk of hospitalisation with COVID-19 was lower in those with one child TRANS and lower still in those with two or more children TRANS, adjusting for age TRANS the hazard ratio (HR) was 0.83 per child TRANS (95% CI 0.70-0.99). On additionally adjusting for sex, socioeconomic deprivation, occupation, professional role, staff/non-staff status, the number of adults TRANS and adolescents in each household, and comorbidity, the HR was 0.89 per child TRANS (95% CI 0.74-1.06). An association of the same magnitude, but more precisely estimated, was obtained for any case of COVID-19 (fully adjusted model, HR per child TRANS 0.89; 95% CI 0.84-0.95). Conclusion Increased household exposure to young children TRANS was associated with an attenuated risk of testing positive for SARS-CoV-2 and appeared to also be associated with an attenuated risk of COVID-19 disease severe enough to require hospitalisation.

    Epidemic Response and Transmission TRANS Dynamics of Coronavirus Disease MESHD (COVID-19) in Khartoum State- Sudan 2020: Study Protocol

    Authors: Mustafa Khidir Mustafa Elnimeiri; Mohanad Kamaleldin Mahmoud Ibrahim; Shahenaz Seifaldeen Mustafa Satti

    doi:10.21203/ Date: 2020-09-19 Source: ResearchSquare

    Background: A novel Coronavirus was identified as severe acute respiratory syndrome Coronavirus 2 MESHD (SARS-CoV-2), and the syndrome of clinical manifestation was named (COVID-19). Consequently, on Jan 30, 2020, the World Health Organization (WHO) declared the outbreak as a pandemic and a public health emergency of international concern. The objectives of this research are to investigate the response of the health system at different levels towards the control of the COVID-19 epidemic and to explore the COVID-19 transmission TRANS dynamics among Sudanese community. Methods: A community and institutional-based cross sectional based study will be conducted in Khartoum State include all the seven localities. The sample size of participant is estimated at 920 using the population formula (n=N/1+ (n*d2)) and considering the response rate. The sample will be drawn using multistage cluster sampling. Data will be collected using interview with key informant and concerned bodies/institutes involved in the response at both the federal and Khartoum State levels. Administered pre-coded, pretested closed ended questionnaire will be developed to collect data from community participants. Data will be managed and analyzed using Statistical Package for Social Sciences version 21. Analysis is mostly univariate descriptive and bi-variate with Chi Square & Fischer Exact tests analysis to find associations between variables of interest.Discussion: This study is expected to evaluate the extent and magnitude of the epidemic response at different levels in addition to the adequacy of the epidemic response. The study participants will be screened to estimate proportion of individuals per age TRANS strata who show sero-positivity for virus infection MESHD, thus it will estimate the percentages of individuals reporting symptoms/signs of infection MESHD and asymptomatic TRANS fraction. The results of this study will strengthen the current interventional approaches of COVID-19 epidemic control and will provide set of database for better planning and implementation of COVID-19 control across the country. It will contribute to in-depth understanding of the COVID-19 transmission TRANS dynamics among Sudanese community and will improve the community awareness about COVID-19.

    SARS-CoV-2 S Protein Binding hACE2: Viral Entry, Pathogenesis, Prognosis, and Potential Therapeutic Targets

    Authors: Lobna Al-Zaidan; Sarra Mestiri; Afsheen Raza; Maysaloun Merhi; Varghese Inchakalody; Queenie Fernandez; Nassiba Taib; Shahab Uddin; Said Dermime

    id:10.20944/preprints202009.0420.v1 Date: 2020-09-18 Source:

    Pneumonia HP cases of unknown etiology in Wuhan, China, were reported to the WHO on 31st of December 2019. Later the pathogen was reported to be a novel coronavirus designated Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) that causes Coronavirus Disease MESHD 2019 (COVID-19). SARS-CoV-2 is a novel pathogenic beta coronavirus that infects MESHD humans causing severe respiratory illness MESHD. However, multifarious factors can contribute to the susceptibility to COVID-19 related morbidity and mortality such as age TRANS, gender TRANS and underlying comorbidities. Importantly, SARS-CoV and SARS-CoV-2 MESHD entry into the host cells is mediated via ACE2 receptor. However, ACE2 receptor binding affinity to SARS-CoV-2 is 4 folds higher than that to SARS-CoV MESHD. Identification of different aspects such as binding affinity, differential antigenic profiles of spike glycoproteins, and ACE2 polymorphisms might influence the investigation of potential therapeutic strategies targeting SARS-CoV-2/ACE2 binding interface. Here we aim to elaborate on SARS-CoV-2 S1/ACE2 ligand that facilitates viral internalization as well as to highlight the differences between SARS-CoVs binding affinity to ACE2. We also discuss the possible immunogenic sequences of spike glycoprotein and the effect of ACE2 polymorphism on viral binding/infectivity and host susceptibility to disease. Furthermore, targeting of ACE2 will be discussed to understand its role in therapeutics.

    Dilated Cardiomyopathy HP Dilated Cardiomyopathy MESHD in a child TRANS with COVID-19

    Authors: Rashmi Kishore; Avinash Choudekar; Ashit Bhusan Xess; Lalit Dar; Rahul Kumar Anand; Anita Saxena; Sushil Kumar Kabra

    doi:10.21203/ Date: 2020-09-17 Source: ResearchSquare

    The coronavirus disease MESHD (COVID-19) though primarily causes respiratory tract infection HP respiratory tract infection MESHD, various extra-pulmonary complications have also been reported. We hereby report dilated cardiomyopathy HP dilated cardiomyopathy MESHD in a one-year old premorbidly healthy boy with COVID-19 infection MESHD who had a poor outcome.

    Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan

    Authors: Xiaojuan Peng; Qi Qi Liu; Zhaolin Chen; Guiyan Wen; Qing Li; Yanfang Chen; Jie Xiong; Xinzhou Meng; Yuanjin Ding; Ying Shi; Shaohui Tang

    doi:10.21203/ Date: 2020-09-11 Source: ResearchSquare

    Background: Moderate cases account for the majority in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD and can also progress to severe/critical condition. Here, we investigated the clinical course and management of hospitalized moderate SARS-CoV-2 patients.Methods: The medical records and follow-up data were analyzed from the SARS-CoV-2 patients outside Wuhan.Results: A total of 73 moderate patients (38 men, 35 women) were included, with median age TRANS of 47.0 (38.5-57.5) years. Among them, only one patient (1.4%) died using active treatment to improve symptoms. The median duration of the four main symptoms cough HP, fever HP fever MESHD, chest tightness HP chest tightness MESHD, and fatigue HP fatigue MESHD were about 1-2 weeks; the median duration of the positive nucleic acid test (NAT) results for SARS-CoV-2 was slightly more than 2 weeks; the median hospitalization time was almost four weeks in 72 moderate survivors. The duration of cough HP cough MESHD and fever HP fever MESHD was positively correlated with the duration of the positive NAT results. On admission, 50% had lymphopenia HP lymphopenia MESHD; less than 30% had abnormal blood SERO biochemistry findings involving hyperglycemia HP hyperglycemia MESHD, liver function and myocardial enzymes. At discharge, the laboratory indexes were substantially improved. Two weeks after discharge, 5.6% survivors experienced a recurrence of the positive NAT results. Conclusions: Moderate SARS-CoV-2 patients have a good prognosis by the active treatment. After discharge, it is necessary that moderate survivors undergo at least a 2-week collective medical observation in quarantine places, which can identify and treat a proportion of patients with re-positive NAT results and to prevent the spread of the potential sources of infection MESHD.

    Diagnosis of Coronavirus disease MESHD by measuring serum SERO concentrations of IL-6 and blood SERO Ferritin

    Authors: Parviz Yazdanpanah; Farzad Vafaei; Saeed Javdansirat; Jalal pouranfard; Sajad Afrouz

    doi:10.21203/ Date: 2020-09-09 Source: ResearchSquare

    Objectives: Coronavirus disease MESHD 2019 (COVID-19) associated by infection MESHD and high death rate. The unresolved questions about the fatality rate of COVID-19 is most probably related to cytokine storm syndrome. There is currently no specific medication. Understanding the pathogenic pathway of this disease will lead to production of treatment and decreases of death MESHD rate. The aim of this study is to investigate changes of peripheral blood SERO parameters (Interleukin-6 and Ferritin) in COVID-19 patients, which may be beneficial in the management of patients.Methods: In this case-control study, we collected data of 270 subjects in two groups including 133 patients with severe type COVID-19 (case) and 137 patients with nonsevere (control) between March 20 and May 21, 2020, and the clinical symptoms and inflammatory indications of patients diagnosed by laboratory test in Shahid Jalil hospital of Yasuj University of medical Sciences were collected to explore potential markers for disease monitoring. The data were analyzed by SPSS software version 20. Descriptive statistics, T-test and bivariate correlation tests were used to analyze. Results: The enrolled COVID-19 patients consisted of 53.4% males TRANS and 46.6% females TRANS with the medium age TRANS of 45.56±18.55 years and there were 50.04% males TRANS and 49.6% females TRANS with the medium age TRANS of 45.59±17.0 years for non COVID-19 patients. There was no significant difference in the age TRANS and sex ratio between two population under study. The proportion interstitial abnormalities MESHD evidenced by CT imaging in COVID-19 patients was 91.0%, while, 4.4% abnormalities was found in non COVID-19 patients. The frequency of positive RT-PCR test for case and control groups were 88.0% and 3.6%, respectively. The mean IL-6 and Ferritin levels and hematological parameters in two groups of patients with COVID-19 and non- COVID-19, were significantly different across all comparisons.There was a direct positively correlated between serum SERO level of IL-6, Ferritin levels and hematological parameters including WBC, Lymphocytes, Neutrophils and Hb, except for platelets (negatively correlate),  with COVID-19. Conclusions: In conclusion, inflammatory markers specifically IL-6 and Ferritin and hematological parameters (WBC, Lymphocytes, Neutrophils, Platelet and Hb) were correlated with the severity of COVID-19. Measurement of IL-6, Ferritin and hematological MESHD indices might be workable tests to diagnosis and prognosis of patients with COVID-19. 

    Antibody SERO Responses to SARS-CoV-2 in Coronavirus Diseases MESHD 2019 Patients with Different Severity

    Authors: Ekasit Kowitdamrong; Thanyawee Puthanakit; Watsamon Jantarabenjakul; Eakachai Prompetchara; Pintip Suchartlikitwong; Opass Putcharoen; Nattiya Hirankarn; Ke Lan; Yu Chen; Huabin Zhao

    doi:10.1101/2020.09.06.20189480 Date: 2020-09-08 Source: medRxiv

    Background: More understanding of antibody SERO responses in the SARS-CoV-2 infected MESHD population is useful for vaccine development. Aim: To investigate SARS-CoV-2 IgA MESHD and IgG among COVID-19 Thai patients with different severity. Methods: We used plasma SERO from 118 adult TRANS patients who have confirmed SARS-CoV-2 infection MESHD and 49 patients under investigation without infection MESHD, 20 patients with other respiratory infections MESHD, and 102 healthy controls. Anti-SARS-CoV-2 IgA and IgG were performed by enzyme-linked immunosorbent assay SERO from Euroimmun. The optical density ratio cut off for positive test was 1.1 for IgA and 0.8 for IgG. The association of antibody SERO response with the severity of diseases and the day of symptoms was performed. Results: From Mar 10 to May 31, 2020, 289 participants were enrolled, and 384 samples were analyzed. Patients were categorized by clinical manifestations to mild (n=59), moderate (n=27) and severe (n=32). The overall sensitivity SERO of IgA and IgG from samples collected after day 7 is 87.9% (95% CI 79.8-93.6) and 84.8% (95% CI 76.2-91.3), respectively. The severe group had a significantly higher level of specific IgA and IgG to S1 antigen compared to the mild group. All moderate to severe patients have specific IgG while 20% of the mild group did not have any IgG detected after two weeks. Interestingly, SARS-CoV-2 IgG level was significantly higher in males TRANS compared to females TRANS among the severe group (p=0.003). Conclusion: The serologic test SERO for SARS-CoV-2 has high sensitivity SERO after the second week after onset of illness. Serological response differs among patients with different severity and different sex.

    On Cancer, COVID-19 and CT Scan: A Monocentric Retrospective Study

    Authors: Francesca Martini; Andrea D'Alessio; Federico Bracchi; Daniela Di Mauro; Anna Fargnoli; Marco Motta; Cristina Giussani; Marco Meazza Prina; Giovanni Gobbin; Monica Taverna

    id:10.20944/preprints202009.0075.v1 Date: 2020-09-04 Source:

    Background The acknowledgment of computed tomography (CT) defined diagnosis in high prevalence SERO northern Italy may identify more patients with Coronavirus Disease MESHD-2019 (COVID 19) infection MESHD, than RT-PCR alone. Methods We retrospectively reviewed 148 chest CT scans of oncological patients who were referred to the Radiological Unit of Policlinico S. Marco from 1st of February 2020 to 30th of April 2020, during the Covid-19 outbreak in Bergamo area. Therefore, we analyzed RT-PCR tests of these 148 patients. Results Among 32 patients with diagnosis of COVID-19 infection MESHD: 17 patients were asymptomatic TRANS or had mild symptoms (53.1%), while 15 developed severe disease (46.8%). The incidence of COVID-19 infection MESHD is 22.9%, the mortality rate is 18.8%. Severe COVID-19 disease is associated with higher median age TRANS. We did not find any correlation between disease severity and sex, smoke or cardiovascular comorbidities. Remarkably, patients who were on treatment developed milder disease MESHD than cancer MESHD patients who were not on treatment. Conclusions The acceptance of CT-defined diagnosis in high prevalence SERO area like Bergamo highlighted a larger number of COVID-19 oncological population than RT-PCR alone, in particular asymptomatic TRANS and mild symptomatic patients. We observed that actively treated patients had milder disease, according to previous studies that suggested a protective role of immunosuppression.

    SARS-CoV-2 Viral RNA Load Dynamics in the Nasopharynx of Infected Children TRANS

    Authors: Kai-qian Kam; Koh Cheng Thoon; Matthias Maiwald; Chia Yin Chong; Han Yang Soong; Liat Hui Loo; Woon Hui Natalie Tan; Jiahui Li; Karen Donceras Nadua; Chee Fu Yung; Norbert Kaiser; Hannes Ganzer; Mathias Strohle; Andreas Walser; Dorothee von Laer; Lothar Hennighausen; Changqing Lin; Qinghua Hu; Tie Song; Ruifu Yang; Xiaoyu Zhang; Kai Sun; Pieter S. Hiemstra; Bruce A. Ponder; Mika J Makela; Kristiina Malmstrom; Robert C. Rintoul; Paul A. Reyfman; Fabian J. Theis; Corry-A Brandsma; Ian Adcock; Wim Timens; Cheng J. Xu; Maarten van den Berge; Roland F. Schwarz; Gerard H. Koppelman; Martijn C. Nawijn; Alen Faiz

    doi:10.1101/2020.08.31.20185488 Date: 2020-09-02 Source: medRxiv

    It is important to understand the temporal trend of pediatric severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) viral load to estimate the transmission TRANS potential of children TRANS in schools and communities. We determined differences in SARS-CoV-2 viral load dynamics between nasopharyngeal samples of infected asymptomatic TRANS and symptomatic children TRANS. The daily cycle threshold values of SARS-CoV-2 in the nasopharynx of a cohort of infected children TRANS were collected for analysis. Among 17 infected children TRANS, 10 (58.8%) were symptomatic. Symptomatic children TRANS, when compared to asymptomatic TRANS children TRANS, had higher viral load (mean cycle threshold on day 7 of illness 28.6 versus 36.7, p = 0.02). Peak SARS-CoV-2 viral loads occured around days 2-3 of illness/days of diagnosis in infected children TRANS. After adjusting for the estimated date of infection MESHD, the higher SARS-CoV-2 viral loads in symptomatic children TRANS remained. We postulate that symptomatic SARS-CoV-2-infected MESHD children TRANS may have higher transmissibility TRANS than asymptomatic TRANS children TRANS. As peak viral load in infected children TRANS occurred in the early stage of illness, viral shedding and transmission TRANS in the pre-symptomatic phase probable. Our study highlights the importance of screening for SARS-CoV-2 in children TRANS with epidemiological risk factors, even when they are asymptomatic TRANS in order to improve containment of the virus in the community, including educational settings.

    Seroprevalence SERO and immunity of SARS-CoV-2 infection MESHD in children TRANS and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study

    Authors: Agne Ulyte; Thomas Radtke; Irene Abela; Sarah H Haile; Julia Braun; Ruedi Jung; Christoph Berger; Alexandra Trkola; Jan Fehr; Milo A Puhan; Susi Kriemler; Anel Nurtay; Lucie Abeler-Dörner; David G Bonsall; Michael V McConnell; Shawn O'Banion; Christophe Fraser; Scott Roberts; Jose A. Gonzalez; Marciano Sablad; Rodrigo Yelin; Wendy Taylor; Kiyoshi Tachikawa; Suezanne Parker; Priya Karmali; Jared Davis; Sean M Sullivan; Steve G. Hughes; Pad Chivukula; Eng Eong Ooi

    doi:10.1101/2020.08.30.20184671 Date: 2020-09-02 Source: medRxiv

    Introduction Seroprevalence SERO and transmission TRANS routes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in children TRANS and adolescents, especially in school setting, are not clear. Resulting uncertainty is reflected in very different decisions on school closures and reopenings across countries. The aim of this longitudinal cohort study is to assess the extent and patterns of seroprevalence SERO of SARS-CoV-2 antibodies SERO in school-attending children TRANS repeatedly. It will examine risk factors for infection MESHD, relationship between seropositivity and symptoms, and temporal persistence of antibodies SERO. Additionally, it will include testing of school personnel and parents TRANS. Methods and analysis The study (Ciao Corona) will enroll a regionally representative, random sample of schools in the canton of Zurich, where 18% of the Swiss population live. Children TRANS aged TRANS 5 to 16 years, attending classes in primary and secondary schools are invited. Venous blood MESHD blood SERO and saliva samples are collected for SARS-CoV-2 serological testing SERO after the first wave of infections (June/July 2020), in fall HP (October/November 2020), and after winter (March/April 2021). Venous blood MESHD blood SERO is also collected for serological testing SERO of parents TRANS and school personnel. Bi-monthly questionnaires to children TRANS, parents TRANS and school personnel cover SARS-CoV-2 symptoms MESHD and tests, health, preventive behavior, lifestyle and quality of life information. Total seroprevalence SERO and cumulative incidence will be calculated. Hierarchical Bayesian logistic regression models will account for sensitivity SERO and specificity of the serological test SERO in the analyses and for the complex sampling structure, i.e., clustering within classes and schools. Ethics and dissemination The study was approved by the Ethics Committee of the Canton of Zurich, Switzerland (2020-01336). The results of this study will be published in peer-reviewed journals and will be made available to study participants and participating schools, the Federal Office of Public Health, and the Educational Department of the canton of Zurich. Trial registration number NCT04448717.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.